No Deal Was Reached In Mylan IP Row, Endo Tells Fed. Circ.
Endo Pharmaceuticals Inc. urged a Federal Circuit panel Monday to nix a disputed settlement agreement with Mylan Pharmaceuticals Inc. over its infringement of Endo's patent for the migraine medication Frova, alleging...To view the full article, register now.
Already a subscriber? Click here to view full article